ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Lessened by Stonepine Capital Management LLC

Stonepine Capital Management LLC lowered its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 33.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,241,032 shares of the biotechnology company's stock after selling 628,968 shares during the period. ADMA Biologics accounts for 17.2% of Stonepine Capital Management LLC's holdings, making the stock its biggest position. Stonepine Capital Management LLC owned 0.52% of ADMA Biologics worth $21,284,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics in the fourth quarter worth $19,076,000. Allspring Global Investments Holdings LLC raised its holdings in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Veracity Capital LLC raised its holdings in shares of ADMA Biologics by 117.0% during the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock worth $796,000 after purchasing an additional 25,030 shares during the last quarter. Nkcfo LLC purchased a new position in shares of ADMA Biologics during the fourth quarter worth $325,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of ADMA Biologics by 272.5% during the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock worth $13,159,000 after purchasing an additional 561,310 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on ADMA shares. StockNews.com cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, Raymond James raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $24.25.

ADMA Biologics Trading Down 1.6%

ADMA stock traded down $0.32 during trading on Wednesday, reaching $20.12. 2,405,413 shares of the stock were exchanged, compared to its average volume of 3,702,822. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average price of $20.61 and a 200-day moving average price of $18.90. ADMA Biologics, Inc. has a 1 year low of $9.35 and a 1 year high of $25.67. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of 71.86 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. ADMA Biologics's revenue was up 40.2% on a year-over-year basis. During the same period last year, the firm posted $0.08 earnings per share. On average, research analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.